Inspire Medical Q2 revenue $91.4M (+73%), net loss $14.5M; FY guidance raised to $354M-$362M

Inspire Medical Systems, Inc.

2022-Q2 EPS reported -$1.13 revenue$160,768,000

Q2 revenue $91.4M (+73% YoY); U.S. $87.9M (+78%), ex-U.S. $3.5M (-3% due to FX).
GAAP net loss $14.5M ($0.53 diluted EPS) vs $13.1M ($0.48) prior year; gross margin 84.5% (down from 85.8%).
FY2022 revenue guidance raised to $354M-$362M (from $336M-$344M); gross margin guidance lowered to 83%-85%.
Activated 52 new U.S. centers in Q2 (total 785); added 17 U.S. sales territories (total 191).
Received FDA approval for expanded full-body MRI; Breakthrough Device Designation for expanded AHI/BMI indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.